TD Cowen Reiterates Buy Rating for Twist Bioscience
TD Cowen maintains its bullish stance on Twist Bioscience with a price target of $89.
Key Points
- TD Cowen reiterated its buy rating for Twist Bioscience Corporation (NasdaqGS:TWST) on June 15, 2026, with a price target of $89.
- Twist Bioscience's stock is trading near $76.17, with a market cap of approximately $4.74 billion and a forward P/E ratio not meaningful due to lack of profitability.
- Other analysts like Canaccord Genuity and Piper Sandler also initiated buy ratings, with targets of $90 and $85, respectively.
TD Cowen has reiterated its buy rating for Twist Bioscience Corporation (NasdaqGS:TWST) on June 15, 2026, setting a price target of $89. This signals continued confidence in the company's prospects, as the stock currently trades around $76.17.
Twist Bioscience Stock Snapshot
Shares of NasdaqGS:TWST are trading near $76.17. Twist Bioscience has a market cap of approximately $4.74 billion. While the company isn't currently profitable, with a negative forward P/E ratio, it shows potential growth in the healthcare sector. The stock's 52-week range is between $23.3 and $80.5, with a 50-day moving average of $59.79 and a 200-day moving average of $42.04. Twist Bioscience's beta is relatively high at 2.214, indicating more volatility compared to the broader market.
Other Institutional Activity in Twist Bioscience
Several institutional investors have made moves in Twist Bioscience recently. Artisan Partners Limited Partnership increased its holdings by 537,572 shares, bringing its total to 6,367,777 shares valued at about $302.6 million. On the other hand, ARK Investment Management LLC reduced its position by 1,216,762 shares, now holding 6,342,733 shares worth approximately $301.4 million. BlackRock, Inc. also trimmed its stake by 340,610 shares, ending with 5,554,362 shares valued at $263.9 million.
Insider Buying and Selling at Twist Bioscience Corporation
Several insiders at Twist Bioscience have recently sold shares. On June 8, 2026, Dennis Cho, the Senior Vice President and Chief Legal Officer, sold 402 shares at an average price of $69.84. CEO Emily Leproust also sold 2,265 shares on the same day at the same price. Other executives, including Paula Green, the SVP of Human Resources, and Robert Werner, the Chief Accounting Officer, also sold shares around this time.
Analysts Set New Price Targets
Analysts have been actively covering Twist Bioscience. On June 15, 2026, Canaccord Genuity initiated coverage with a buy rating and a $90 price target. Piper Sandler also initiated a buy rating with an $85 target on June 11, 2026. Overall, the consensus among nine analysts is a strong buy, with an average price target of about $66.67.
About Twist Bioscience
Twist Bioscience Corporation, based in South San Francisco, California, specializes in manufacturing synthetic DNA-based products. The company serves various sectors, including healthcare, diagnostics, and research, by providing synthetic genes, oligo pools, and NGS tools. Founded in 2013 and led by CEO Dr. Emily Marine Leproust, Twist Bioscience employs 979 people and collaborates with industry players like bitBiome Inc.
Bottom Line
TD Cowen's reaffirmation of a buy rating with a target of $89 reflects ongoing confidence in Twist Bioscience's growth potential. While the company is not yet profitable, its innovative products in synthetic DNA and research tools keep it in focus for investors. As always, remember that analyst ratings and projections are based on past data and market conditions, which can change.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.